Active Ingredient History
Siltuximab is a chimeric monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of neoplastic diseases: metastatic renal cell cancer, prostate cancer, other types of cancer, and for Castleman's disease. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Renal Cell (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
COVID-19 (Phase 3)
Cytokine Release Syndrome (Phase 2)
Diabetes Mellitus, Type 1 (Early Phase 1)
Head and Neck Neoplasms (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Immunoglobulin Light-chain Amyloidosis (Phase 2)
Kidney Neoplasms (Phase 2)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Multiple Myeloma (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Neoplasms, Plasma Cell (Phase 1)
Neurotoxicity Syndromes (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 1/Phase 2)
Pneumonia (Phase 3)
Polycythemia Vera (Early Phase 1)
Primary Myelofibrosis (Early Phase 1)
Prostatic Neoplasms (Phase 2)
Psychotic Disorders (Phase 1/Phase 2)
Respiratory Distress Syndrome (Phase 3)
Respiratory Tract Diseases (Phase 3)
Respiratory Tract Infections (Phase 3)
Schizophrenia (Phase 1/Phase 2)
Thrombocytopenia (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
